Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Controlled release and taste masking oral pharmaceutical composition|
|Abstract:||Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.|
|Inventor(s):||Villa; Roberto (Lecco, IT), Pedrani; Massimo (Cignese, IT), Ajani; Mauro (Milan, IT), Fossati; Lorenzo (Milan, IT)|
|Assignee:||Cosmo Technologies Limited (Wicklow, IE)|
|Filing Date:||Mar 20, 2006|
|Claims:||1. A controlled release oral pharmaceutical composition in a tablet form containing mesalamine as the active ingredient, consisting essentially of: a) a matrix, consisting of lipophilic compounds with a melting point lower than 90.degree. C. in which the active ingredient is at least partially dispersed, said lipophilic compounds being a combination of at least one wax and at least one saturated fatty acid or unsaturated fatty acid; b) a hydrophilic matrix in which the lipophilic matrix is dispersed, said hydrophilic matrix consisting of carboxyalkylcellulose; and c) a matrix consisting of amphiphilic compounds being selected from the group consisting of polar lipids of type I, polar lipids of type II and glycols partially etherified with C1-C4 alkyl chains, in which the active ingredient is at least partially dispersed, said matrix of amphiphilic compounds being dispersed in the hydrophilic matrix, wherein, the matrix of lipophilic compounds, the matrix of hydrophilic compounds, and the matrix of amphiphilic compounds, in combination, provide controlled release. |
2. The composition as claimed in claim 1, wherein the saturated fatty acid is selected from the group consisting of palmitic, stearic, myristic, lauric, laurilic or oleic acids, and mixtures thereof.
3. The composition as claimed in claim 1, wherein the saturated fatty acid is stearic acid.
4. The composition as claimed in claim 1, wherein the melting point of the lipophilic matrix is from 40.degree. C. to 90.degree. C.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.